CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amgen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amgen Inc
One Amgen Center Drive
Phone: (805) 447-1000p:805 447-1000 THOUSAND OAKS, CA  91320  United States Ticker: AMGNAMGN
Business Summary
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Robert A.Bradway 61 1/1/2013 4/10/2007
Chief Financial Officer, Executive Vice President Peter H.Griffith 65 1/1/2020 10/23/2019
Executive Vice President, Chief Technology Officer David M.Reese 61 12/18/2023 7/26/2018
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AMGEN INC.
Horizon Pharma Investment Ltd Bermuda
Horizon Therapeutics PLC 70 St. Stephen's Green DUBLIN Ireland
20 additional Subsidiary records available in full report.

Business Names
Business Name
Amgen (Europe) GmbH
Amgen Australia Pty Ltd
Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd.
59 additional Business Names available in full report.

General Information
Number of Employees: 26,700 (As of 12/31/2023)
Outstanding Shares: 537,532,723 (As of 10/25/2024)
Shareholders: 4,614
Stock Exchange: NASD
Federal Tax Id: 953540776
Fax Number: (805) 447-1010
Email Address: Investor.Relations@Amgen.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024